Successful treatment of the face post acne erythema using a topically applied selective alpha 1-Adrenergic receptor agonist, oxymetazoline 1.5%, a controlled left to right face comparative trial

Agamia, Naglaa; Essawy, Marwa M.; Kassem, Amira B.

doi:10.1080/09546634.2020.1789045

Cited by 13 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sample size was calculated using G Power 3.1.9.42018. Based on an effect size between two independent groups of triple combination and placebo of 0.9 14 alpha error of 0.05, power of 80% the minimum required sample size was calculated to be 40 patients in each group (two sides of the face).…”

Section: Methodsmentioning

confidence: 99%

“…Liposomal cream, prepared analogously, served as the placebo lipocream for this study. 14,18 Patients were allowed to use topical anti acne treatment (e.g., topical retinoids) and/or systemic antibiotic (e.g., doxycycline and azithromycin) during acne flare or to maintain the disease control.…”

Section: Drug Preparationmentioning

confidence: 99%

“… Subjective degrees of satisfaction were also evaluated. Patients assessed treatment outcome as: No improvement (very dissatisfied), mild improvement (dissatisfied), good improvement (satisfied) and excellent improvement (very satisfied) after 3 months of treatment 14 Morphometric evaluation of erythema : For computer‐aided evaluation of the treatment efficacy, pre‐ and post‐treatment, medical photographs were analyzed to distinguish color differences in PIE from surrounding normal skin.…”

Section: Treatment Protocolmentioning

confidence: 99%

“…In ours as well as in previous studies, the incidence of treatment related adverse effects was highest during the first 4 weeks of treatment and disappeared gradually. 14 The decline in rate of improvement in the 3rd month of treatment was noticed due to loss of efficacy with prolonged use due to desensitization (tachyphylaxis) and stationary response after the third month related to OXZ These AEs was reported in rosacea patients treated with topical OXZ. 28,29 But at the end of the follow-up period, neither of our patients' exhibited relapses with continuous treatment and PAE was still significantly lower than that at the time of enrolment.…”

Section: Clinical Assessment For Paementioning

confidence: 99%

“…11 Short-pulsed 1064 nm laser has been tried for atrophic post acne scar (PAS) and proved to be beneficial in PAE improvement and has the advantage of being relatively pain free. 12 They all showed significant results in improving PAE, they have the disadvantage of being relatively high cost, can cause pigmentary changes, some are painful, 13 and downtime needed after sessions before patients return to their daily life routine and they are not easily available at all outpatient clinics, unlike topical treatment such as oxymetazoline (OXZ), 14 brimonidine, 5 and TXA 6,15 which can be easily prepared and easily applied by patients at home.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema

Agamia

El‐Nagdy

Elariny

2022

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Persistent post acne erythema (PAE) is common cosmetically unacceptable and challenging sequelae of acne lesions. Tranexamic acid (TXA) is an antifibrinolytic agent that shows a positive effect on wound healing in several studies, and it showed benefits in treating skin diseases like melasma, rosacea erythema and ultraviolet induced pigmentations. Oxymetazoline (OXZ) is a synthetic, highly selective agonist for alpha 1A‐adrenoceptor. It is a potent vasoconstrictor. OXZ hydrochloride 1% cream was approved by the FDA in January 2017 as a topical treatment for persistent facial erythema in rosacea patients. Brimonidine tartrate (BMT) is highly selective α2 adrenergic receptor agonist, results in direct, potent vasoconstriction of small arterioles and veins. In 2013, brimonidine 0.33% gel was the first topical therapy to be FDA approved for the treatment of persistent facial erythema from rosacea. To evaluate the efficacy and safety of topical triple combination (TXA 5% + OXZ 1.5% + BMT 0.33%) in the treatment of PAE planned as split face comparative study. This study was conducted on 40 patients diagnosed with persistent PAE for at least 3 months, the right side of the face was treated with topical triple combination in liposomal base and was compared to the left side to which topical lipocream (placebo) was applied as a control. Our treatment plan lasted for 3 months. According to the investigator's global assessment of photographs and computerized analysis of erythema using image analysis software, topical triple combination applied on the right side of face was significantly effective in diminishing PAE when compared to topical placebo left side. Topical triple combination is a safe and cost‐effective treatment for PAE.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Drug Preparationmentioning

confidence: 99%